Iconic Therapeutics, Inc. is a privately held clinical-stage biopharmaceutical company focused on development of novel therapeutics for the treatment of serious eye disorders. The company's lead asset is hI-con1, a human chimeric protein targeting tissue factor. The company has operations in Atlanta, GA and South San Francisco, CA.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/16/14 | $20,000,000 | Series B |
H.I.G. Capital Lundbeckfond Ventures MPM Capital | undisclosed |
| 01/12/16 | $40,000,000 | Series C |
Cormorant Asset Management HBM Healthcare Investments HIG Growth Capital Lundbeckfund Ventures MPM Capital Osage University Partners | undisclosed |
| 08/10/16 | $10,000,000 | Series C |
Xeraya Capital | undisclosed |
